GlassScriptPhysician profile
Jennifer D Shaw
NPI 1437581766
$2,476.15
in general payments reported to CMS, 2019-2025
31 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $247 · 2021: $736 · 2022: $389 · 2023: $402 · 2024: $389 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $478.50 | 2020-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $387.06 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $343.38 | 2021-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $208.31 | 2021-2025 | Vraylar |
| Merck Sharp & Dohme LLC | $110.64 | 2020-2023 | Verquvo, Belsomra |
| Pfizer INC. | $106.12 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $103.08 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $88.49 | 2021-2022 | |
| Lilly USA, LLC | $79.63 | 2021-2023 | Mounjaro |
| Mylan Specialty L.P. | $65.48 | 2020-2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $52.99 | 2025 | Voquezna |
| Allergan, INC. | $50.08 | 2020 | |
| Boston Scientific Corporation | $37.84 | 2022-2025 | Intracept |
| E.R. Squibb & Sons, L.L.C. | $31.81 | 2023-2025 | Eliquis |
| Incyte Corporation | $31.50 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $30.56 | 2023 | Myrisk |
| Janssen Pharmaceuticals, INC | $29.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.04 | 2022-2024 | |
| Sanofi Pasteur INC. | $23.94 | 2023 | |
| Organogenesis INC. | $21.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.33 | 2021 | |
| Viatris Specialty LLC | $16.46 | 2025 | Yupelri |
| Lundbeck LLC | $16.44 | 2024 | Rexulti |
| Smith+Nephew, INC. | $16.43 | 2021 | |
| Electromed, INC. | $15.75 | 2025 | Smartvest |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.37 | 2025 | Caplyta |
| Eisai INC. | $14.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.36 | 2023 | Breztri |
| Glaxosmithkline, LLC. | $14.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.57 | 2021 | |
| Genzyme Corporation | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.